161 selected items - PubMed - NCBI

Warning: The NCBI web site requires JavaScript to function. more...

My NCBI Sign In

Result Filters

<< First< Prev

Page of 9

Results: 1 to 20 of 161

1.

Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up.

Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O.

J Viral Hepat. 2012 Feb;19(2):e97-104. doi: 10.1111/j.1365-2893.2011.01512.x. Epub 2011 Oct 4.

PMID:: 22239532; [PubMed - indexed for MEDLINE]

Related citations

2.

Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation.

Grover VP, Pavese N, Koh SB, Wylezinska M, Saxby BK, Gerhard A, Forton DM, Brooks DJ, Thomas HC, Taylor-Robinson SD.

J Viral Hepat. 2012 Feb;19(2):e89-96. doi: 10.1111/j.1365-2893.2011.01510.x. Epub 2011 Oct 17.

PMID:: 22239531; [PubMed - indexed for MEDLINE]

Related citations

3.

Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity.

Bachmetov L, Gal-Tanamy M, Shapira A, Vorobeychik M, Giterman-Galam T, Sathiyamoorthy P, Golan-Goldhirsh A, Benhar I, Tur-Kaspa R, Zemel R.

J Viral Hepat. 2012 Feb;19(2):e81-8. doi: 10.1111/j.1365-2893.2011.01507.x. Epub 2011 Aug 16.

PMID:: 22239530; [PubMed - indexed for MEDLINE]

Related citations

4.

Inhibition of IκB kinase by thalidomide increases hepatitis C virus RNA replication.

Rance E, Tanner JE, Alfieri C.

J Viral Hepat. 2012 Feb;19(2):e73-80. doi: 10.1111/j.1365-2893.2011.01505.x. Epub 2011 Aug 16.

PMID:: 22239529; [PubMed - indexed for MEDLINE]

Related citations

5.

Ischaemic colitis during interferon treatment for chronic hepatitis C: report of two cases and literature review.

Kawaguchi T, Ide T, Itou M, Suetsugu M, Yoshioka S, Sakata M, Taniguchi E, Oriishi T, Sumie S, Tsuruta O, Sata M.

J Viral Hepat. 2012 Feb;19(2):e220-4. doi: 10.1111/j.1365-2893.2011.01501.x. Epub 2011 Aug 4. Review.

PMID:: 22239522; [PubMed - indexed for MEDLINE]

Related citations

6.

Examining hepatitis C virus testing practices in primary care clinics.

Almario CV, Vega M, Trooskin SB, Navarro VJ.

J Viral Hepat. 2012 Feb;19(2):e163-9. doi: 10.1111/j.1365-2893.2011.01539.x. Epub 2011 Nov 17.

PMID:: 22239514; [PubMed - indexed for MEDLINE]

Related citations

7.

Hepatic expression of MxA and OAS1 in an ex vivo liver slice assay independently predicts treatment outcomes in chronic hepatitis C.

Cheng JC, Yeh YJ, Huang YH, Liang KH, Chang ML, Lin CY, Yeh CT.

J Viral Hepat. 2012 Feb;19(2):e154-62. doi: 10.1111/j.1365-2893.2011.01538.x. Epub 2011 Oct 7.

PMID:: 22239513; [PubMed - indexed for MEDLINE]

Related citations

8.

Fibrosis progression under maintenance interferon in hepatitis C is better detected by blood test than liver morphometry.

Calès P, Zarski JP, Marc Chapplain J, Bertrais S, Sturm N, Michelet C, Babany G, Chaigneau J, Eddine Charaf M; multicentric groups (Fibrosys, ANRS HC 12, Fibrostop).

J Viral Hepat. 2012 Feb;19(2):e143-53. doi: 10.1111/j.1365-2893.2011.01531.x. Epub 2011 Oct 30.

PMID:: 22239512; [PubMed - indexed for MEDLINE]

Related citations

9.

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C.

Hayashi N, Okanoue T, Tsubouchi H, Toyota J, Chayama K, Kumada H.

J Viral Hepat. 2012 Feb;19(2):e134-42. doi: 10.1111/j.1365-2893.2011.01528.x. Epub 2011 Nov 8.

PMID:: 22239511; [PubMed - indexed for MEDLINE]

Related citations

10.

Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection.

Miki D, Ohishi W, Ochi H, Hayes CN, Abe H, Tsuge M, Imamura M, Kamatani N, Nakamura Y, Chayama K.

J Viral Hepat. 2012 Feb;19(2):e126-33. doi: 10.1111/j.1365-2893.2011.01516.x. Epub 2011 Sep 14.

PMID:: 22239510; [PubMed - indexed for MEDLINE]

Related citations

11.

Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.

Craxi A, Koutsounas S, Ogurtsov P, Chemello L, Maticic M, Torras J, Diago M, Tartaglione MT, Witthoeft T, Yu X, Faruqi R, Chaudhri E, Pedicone LD, Zuckerman E.

J Viral Hepat. 2012 Feb;19(2):e120-5. doi: 10.1111/j.1365-2893.2011.01515.x. Epub 2011 Sep 19.

PMID:: 22239509; [PubMed - indexed for MEDLINE]

Related citations

12.

Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection.

Yamada I, Suzuki F, Kamiya N, Aoki K, Sakurai Y, Kano M, Matsui H, Kumada H.

J Viral Hepat. 2012 Feb;19(2):e112-9. doi: 10.1111/j.1365-2893.2011.01514.x. Epub 2011 Oct 7.

PMID:: 22239508; [PubMed - indexed for MEDLINE]

Related citations

13.

Prospective study of risk factors for hepatitis C virus acquisition by Caucasian, Hispanic, and Asian American patients.

Ho EY, Ha NB, Ahmed A, Ayoub W, Daugherty T, Garcia G, Cooper A, Keeffe EB, Nguyen MH.

J Viral Hepat. 2012 Feb;19(2):e105-11. doi: 10.1111/j.1365-2893.2011.01513.x. Epub 2011 Oct 7.

PMID:: 22239506; [PubMed - indexed for MEDLINE]

Related citations

14.

CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferon-α therapy and toll-like receptor 3 signalling.

Katsounas A, Trippler M, Wang B, Polis M, Lempicki RA, Kottilil S, Gerken G, Schlaak JF.

J Viral Hepat. 2012 Feb;19(2):128-37. doi: 10.1111/j.1365-2893.2011.01503.x. Epub 2011 Nov 21.

PMID:: 22239502; [PubMed - indexed for MEDLINE]

Related citations

15.

Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b.

Vermehren J, Susser S, Lange CM, Forestier N, Karey U, Hughes E, Ralston R, Tong X, Zeuzem S, Sarrazin C.

J Viral Hepat. 2012 Feb;19(2):120-7. doi: 10.1111/j.1365-2893.2011.01449.x. Epub 2011 Mar 1.

PMID:: 22239501; [PubMed - indexed for MEDLINE]

Related citations

16.

Intravenous drug use: not a barrier to achieving a sustained virological response in HCV infection.

Jafferbhoy H, Miller MH, Dunbar JK, Tait J, McLeod S, Dillon JF.

J Viral Hepat. 2012 Feb;19(2):112-9. doi: 10.1111/j.1365-2893.2011.01446.x. Epub 2011 May 9.

PMID:: 22239500; [PubMed - indexed for MEDLINE]

Related citations

17.

Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin.

Reau N, Hamzeh FM, Lentz E, Zhou X, Jensen D.

J Viral Hepat. 2012 Feb;19(2):94-102. doi: 10.1111/j.1365-2893.2010.01422.x. Epub 2011 Jan 12.

PMID:: 22239499; [PubMed - indexed for MEDLINE]

Related citations

18.

Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis.

Alavian SM, Tabatabaei SV, Behnava B.

J Viral Hepat. 2012 Feb;19(2):88-93. doi: 10.1111/j.1365-2893.2011.01532.x. Epub 2011 Oct 30. Review.

PMID:: 22239498; [PubMed - indexed for MEDLINE]

Related citations

19.

Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.

Stickel F, Helbling B, Heim M, Geier A, Hirschi C, Terziroli B, Wehr K, De Gottardi A, Negro F, Gerlach T.

J Viral Hepat. 2012 Feb;19(2):77-87. doi: 10.1111/j.1365-2893.2011.01527.x. Epub 2011 Oct 18. Review.

PMID:: 22239497; [PubMed - indexed for MEDLINE]

Related citations

20.

Hepatitis C core protein impairs insulin downstream signalling and regulatory role of IGFBP-1 expression.

Alberstein M, Zornitzki T, Zick Y, Knobler H.

J Viral Hepat. 2012 Jan;19(1):65-71. doi: 10.1111/j.1365-2893.2011.01447.x. Epub 2011 May 9.

PMID:: 22187946; [PubMed - in process]

Related citations

<< First< Prev

Page of 9

Supplemental Content

Filters: Manage Filters

Find related data

Recent activity

Clear Turn Off Turn On

Longitudinal changes of the laboratory data of chronic hepatitis C patients with...
Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up.
J Viral Hepat. 2012 Feb ;19(2):e97-104. doi: 10.1111/j.1365-2893.2011.01512.x. Epub 2011 Oct 4 .

PubMed
Comparison of the hepatitis B virus core, surface and polymerase gene substituti...
Comparison of the hepatitis B virus core, surface and polymerase gene substitution rates in chronically infected patients.
J Viral Hepat. 2012 Feb ;19(2):e34-40. doi: 10.1111/j.1365-2893.2011.01506.x. Epub 2011 Aug 16 .

PubMed
The influence of cigarette smoking on haloperidol pharmacokinetics.
The influence of cigarette smoking on haloperidol pharmacokinetics.
Biol Psychiatry. 1990 Sep 15 ;28(6):529-31.

PubMed
Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy ...
Brachytherapy for the treatment of recurrent prostate cancer after radiotherapy or radical prostatectomy.
BJU Int. 2012 Feb ;109 Suppl 1:17-21. doi: 10.1111/j.1464-410X.2011.10826.x.

PubMed
Recommendations for transfusion in ABO-incompatible hematopoietic stem cell tran...
Recommendations for transfusion in ABO-incompatible hematopoietic stem cell transplantation.
Transfusion. 2012 Feb ;52(2):456-8. doi: 10.1111/j.1537-2995.2011.03465.x.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

You are here: NCBI > Literature > PubMed

Write to the Help Desk